If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats
The NDA filing is supported by results from the phase III evERA Breast Cancer study
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
This approval builds on the recent transformation RYBREVANT FASPRO brought to lung cancer care
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
Alto met its enrollment goal with 83 patients across 13 US clinical sites
Iberdomide has the potential to be the first approved CELMoD agent
Subscribe To Our Newsletter & Stay Updated
